(Q43181709)

English

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

scientific article published in February 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Olivier Rixe

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

author name string

Patricia Pautier

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Florence Joly

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Pierre Kerbrat

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Philippe Bougnoux

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Pierre Fumoleau

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Thierry Petit

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

François Ringeisen

8

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Annie Tisseron Carrasco

9

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Catherine Lhommé

10

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

language of work or name

0 references

publication date

1 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

157-162

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

The management of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Significance of epidermal growth factor receptor in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

APL during gefitinib treatment for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Risk of leukemia after platinum-based chemotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.076

7 January 2021

Identifiers

10.1016/J.YGYNO.2009.10.076

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43181709&oldid=1601286697"